Originally Midnight Riders #321 >>71868
So giving males females hormones might help with covid recovery? (why not try HCL, ivermevtin, etc., instead?) Mebbe coz they hope to kill two birds with one stone?
Posting this because it's going to be making the rounds. But it's a study where the only significant difs were on subjectively rated outcomes (nothing objective); PI's also have a potential financial interest in the outcome.
Study: Progesterone Therapy May Improve COVID-19 Outcomes for Men
Clinical Trial at Cedars-Sinai Suggests Injections of Female Hormone May Reduce Disease Severity in Certain Male Patients
Sara Ghandehari, MD
COVID-19 disproportionately affects men compared with women, raising the possibility that a hormone like progesterone may improve clinical outcomes for certain hospitalized men with the disease. New research from Cedars-Sinai published online in the journal Chest supports this hypothesis.
The pilot clinical trial, involving 40 men, is believed to be the first published study to use progesterone to treat male COVID-19 patients whose lung functions have been compromised by the coronavirus. While the findings are promising, larger clinical trials are needed to establish the potential of this experimental therapy, the investigators said.
The study was prompted by multiple reports that men are at higher risk of mortality and severe illness from COVID-19 than are women, according to Sara Ghandehari, MD, director of Pulmonary Rehabilitation in the Women’s Guild Lung Institute at Cedars-Sinai and principal investigator for the trial….
Results:
The study showed that, compared with the control group, patients in the group treated with progesterone scored a median 1.5 points higher on a standard seven-point scale of clinical status after seven days. The scale ranged from a high of 7 ("not hospitalized, no limitations on activities") to 1 ("death").
[SUBJECTIVE MEASURES; no dif on objective measure)
Study Limitations:
The sample size was relatively small and involved mainly white, Hispanic and obese patients with a moderate burden of comorbidities, which increase the risk for worse outcomes. Further, although the clinical trial was randomized and controlled, it was unblinded.
Conflict of interest: Sara Ghandehari and Samuel Pepkowitz report apatent pendingon the method of use of a progesterone agonist for treatment of COVID-19. Victor Tapson reports grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health for ACTT (ACTT 1-3) outside the submitted work.
https://www.cedars-sinai.org/newsroom/study-progesterone-therapy-might-improve-covid-19-outcomes-for-men/